891842-55-0

Basic information

• Product Name: N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylthio)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine
• Synonyms: N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylthio)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine
• CAS NO: 891842-55-0
• Molecular Weight: 816.011
• Mol File: 891842-55-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylthio)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylthio)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine(891842-55-0)
• EPA Substance Registry System: N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylthio)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine(891842-55-0)

Safety Data

• Hazardous Substances Data: 891842-55-0(Hazardous Substances Data)

Upstream product

• 891842-46-9 N-((4-bromo-1-trityl-1H-imidazol-2-yl)(5-ethoxy-2-fluoro-3-isopropoxyphenyl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine 
• 168618-42-6 (2-methylsulfanylphenyl)boronic acid 

Downstream Products

• 891842-56-1 N-((5-ethoxy-2-fluoro-3-isopropoxyphenyl)(4-(2-(methylsulfonyl)phenyl)-1-trityl-1H-imidazol-2-yl)methyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzenamine 

Relevant articles and documents

Heterocyclic compounds as inhibitors of factor VIIa

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.